For the fourth time, Rafarma Pharmaceuticals, Inc. (OTC: RAFA) will attend the "Cognitive Science: New Research" conference. Organized by the Russian Journal of Cognitive Science with the support of the Moscow Institute of Psychoanalysis and the Research Institute of Neuropsychology of Writing and Speech, the event will take place on June 21 and 22. Ilya Shpurov, the chairman of the Rafarma Pharmaceuticals board, is the conference organizing committee member.
Providing an opportunity for cognitive scientists to present recent works and discuss them with their colleagues is one of the main conference's purposes. It is the landmark event for leading scientific centres and universities, which demonstrate academic developments and innovative research in the cognitive sciences, neurosciences and neurotechnologies as part of the conference.
The key feature of this event is the unification of not only specialized scientific disciplines that study the human brain and mental capabilities but also other fields, such as physics, medicine, and computer science. Today, materials scientists, engineers and programmers are actively involved in brain-related technology development.
Biennially more than 200 universities and academic science representatives participate in the conference, including well-known scientists and young researchers from Russia, Israel, Germany, Colombia, and Turkey.
ABOUT RAFARMA PHARMACEUTICALS:
Rafarma Pharmaceuticals is a diversified pharmaceutical company dedicated to the new treatments and solutions development for patients in various fields. Regularly cooperating with leading research institutes and pharmaceutical companies around the world, the business has earned a reputation as a reliable manufacturer and distributor. Rafarma Pharmaceuticals has more than 25 programs in molecular biology, nuclear medicine, immunology, sustainable packaging and many other fields at the moment.
For more information, please visit https://www.noyarp.com
FORWARD-LOOKING STATEMENT:
Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
CONTACTS:
RAFARMA PHARMACEUTICALS
(307) 429-2029
Source: Rafarma Pharmaceuticals, Inc.